WT1-pulsed dendritic cell vaccination for neovascular age-related macular degeneration: a phase I pilot feasibility study
Masaki Nakamura, Shigeo Koido, Tuuse Bito, Hiroshi Horiguchi, Yoko Shimizu, Masamori Shimabuku, Junichi Taguchi, Hisato Gunji, Haruo Sugiyama, Tadashi Nakano · 2026
Read WT1-pulsed dendritic cell vaccination for neovascular age-related macular degeneration: a phase I pilot feasibility study by Masaki Nakamura, Shigeo Koido, Tuuse Bito, Hiroshi Horiguchi, Yoko Shimizu, Masamori Shimabuku, Junichi Taguchi, Hisato Gunji, Haruo Sugiyama, Tadashi Nakano (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13383492.txt.
Description
Masaki Nakamura and co-authors run a first-phase pilot of a dendritic cell vaccine for wet age-related macular degeneration, in a research paper from 2026. The disease is a leading cause of vision loss. Standard injections work, but frequent dosing carries risk and may not address root causes. A gene called WT1 helps drive new vessel growth in the eye.
Two patients first got three monthly eye injections of a standard drug. They then got fifteen vaccine doses under the skin over time. The vaccine was well tolerated, with limited side effects. One patient kept stable eye shape and vision with no added standard drug. The pilot tests safety and immune response.
Catalog record
| CREATOR | Masaki Nakamura, Shigeo Koido, Tuuse Bito, Hiroshi Horiguchi, Yoko Shimizu, Masamori Shimabuku, Junichi Taguchi, Hisato Gunji, Haruo Sugiyama, Tadashi Nakano |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |